Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025.
Shelby Knowles | Bloomberg | Getty Images
Danish pharmaceutical giant Novo Nordisk on Wednesday announced plans to cut roughly 9,000 roles.
“Novo Nordisk today announced a company-wide transformation to simplify its organisation, improve the speed of decision-making, and reallocate resources towards the company’s growth opportunities in diabetes and obesity,” the company, which produces the Wegovy weight loss medication, said in a statement,
“As part of the transformation, Novo Nordisk intends to reduce the global workforce by approximately 9,000 of the 78,400 positions in the company, with around 5,000 reductions expected in Denmark.”
This is a developing story and will be updated shortly.
